本文選題：噻托溴銨　切入點：沙美特羅替卡松　出處：《中國呼吸與危重監(jiān)護雜志》2017年06期 　論文類型：期刊論文

【摘要】：目的 系統(tǒng)評價沙美特羅替卡松聯(lián)合噻托溴銨與單用沙美特羅替卡松治療我國慢性阻塞性肺疾病(簡稱慢阻肺)患者的有效性及安全性。方法 計算機檢索PubMed、Embase、The Cochrane Library(2017年第4期)、CNKI、VIP和WanFang Data數(shù)據(jù)庫,搜集沙美特羅替卡松聯(lián)合噻托溴銨與單用沙美特羅替卡松治療我國慢阻肺患者的相關隨機對照試驗(randomized controlled trials,RCT),檢索時限均為從建庫至2017年4月。由2位評價員按照納入與排除標準獨立篩選文獻、提取資料并評價納入研究的偏倚風險后,采用RevMan 5.3軟件進行Meta分析。結果 共納入30個RCT研究,3 121例患者。Meta分析結果顯示:在有效性方面,與單用沙美特羅替卡松比較,沙美特羅替卡松聯(lián)合噻托溴銨能有效改善慢阻肺患者的FEV_1[MD=0.30,95%CI(0.22,0.39),P0.000 01]、FVC[MD=0.31,95%CI(0.23.0.40),P0.000 01]及FEV_1/FVC[MD=9.07,95%CI(6.69,11.44),P0.00001];在安全性方面,兩組不良反應發(fā)生率無明顯差異[OR=1.17,95%CI(0.83,1.66),P=0.37]。結論 現(xiàn)有證據(jù)表明,應用噻托溴銨聯(lián)合沙美特羅替卡松可改善我國慢阻肺患者的肺功能指標。受納入研究數(shù)量和質(zhì)量限制,上述結論尚需開展更多高質(zhì)量研究予以驗證。
[Abstract]:Objective to evaluate Shah Mette Lo and fluticasone propionate combined with tiotropium alone Shah Mette Lo Tikason Chinese treatment of chronic obstructive pulmonary disease (COPD) the efficacy and safety of patients. Methods we searched PubMed, Embase, The Cochrane Library (2017 fourth), CNKI, VIP and WanFang Data database, randomized controlled collect the test Shah Mette Lo fluticasone propionate combined with tiotropium alone with Shah Mette Lo Tikason in the treatment of Chinese patients with COPD (randomized controlled, trials, RCT) were searched from inception to April 2017. By 2 reviewers independently screened according to the inclusion and exclusion criteria of literature, extracted the data and assessed the risk of bias of included studies. Meta analysis was performed using RevMan 5.3 software. The results of the 30 RCT study included 3121 patients with.Meta, the results showed that: in terms of effectiveness, with Shah Mette Lo 鏇垮崱鏉炬瘮杈，

本文編號：1617110